Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says

theflyonthewall.com

Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options.

View Comments (0)